



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

**Corti et al**

Application No.: **10/622,817**

Filed: **July 18, 2003**

Title: **METHOD FOR DETERMINING THE  
ABILITY OF A COMPOUND TO MODIFY  
THE INTERACTION BETWEEN PARKIN  
AND THE p38 PROTEIN**

Examiner: To Be Assigned

Art Unit: **1614**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 19, 2004

Date of Deposit

Debra Conagher

Signature

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Missing Parts  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

Michael J. Schmelzer, Reg. No. 43,093  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4797  
Telefax (908) 231-2626

Docket No. FRAV2002/0020US NP